Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring

WANG Yiqi; CHANG Luyao; FU Ran; WANG Lingjiao; YU Jing; ZHOU Chunhua

doi:10.6039/j.issn.1001-0408.2022.24.15

您当前的位置：

首页 >

文章列表页 >

Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring

更新时间：2023-02-22

- Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring
- ZHONGGUO YAOFANG Vol. 33, Issue 24, Pages: 3020-3024(2022)
- 作者机构：
  
  1.河北医科大学第一医院临床药学部，石家庄　050000
  2.河北省人工智能临床药学技术创新中心，石家庄　050000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.24.15
  CLC： R969.3;R971⁺.41
- Published：30 December 2022，
  
  Received：18 June 2022，
  
  Revised：30 October 2022，
扫描看全文
王毅奇,常路瑶,付冉等.基于治疗药物监测的氨磺必利剂量校正浓度影响因素分析 ^Δ[J].中国药房,2022,33(24):3020-3024.

WANG Yiqi,CHANG Luyao,FU Ran,et al.Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring[J].ZHONGGUO YAOFANG,2022,33(24):3020-3024.
王毅奇,常路瑶,付冉等.基于治疗药物监测的氨磺必利剂量校正浓度影响因素分析 ^Δ[J].中国药房,2022,33(24):3020-3024. DOI： 10.6039/j.issn.1001-0408.2022.24.15.

WANG Yiqi,CHANG Luyao,FU Ran,et al.Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring[J].ZHONGGUO YAOFANG,2022,33(24):3020-3024. DOI： 10.6039/j.issn.1001-0408.2022.24.15.

摘要

目的

分析氨磺必利剂量校正浓度（

）的影响因素，为该药的临床合理应用提供参考。

方法

回顾性收集河北医科大学第一医院精神卫生中心2021年3－11月进行氨磺必利治疗药物监测的精神分裂症住院患者的末次血药浓度监测结果及相关病历资料，分析其年龄、性别、体质量指数（BMI）、血清肌酐水平、联合用药对氨磺必利

值的影响。

结果

共纳入精神分裂症住院患者133例，其氨磺必利中位剂量为600.00 mg/d，中位血清浓度为332.57 ng/mL，中位

值为0.61 ng·d/（mL·mg）；49例患者的血清药物浓度在相关指南推荐参考范围（100～320 ng/mL）内，27例患者超过实验室警戒水平（640 ng/mL）。不同性别患者的给药剂量、血清药物浓度、

值比较，差异均无统计学意义（

＞0.05）；未成年患者的血清药物浓度显著低于成年患者（

＜0.05），但其给药剂量、

值与成年患者比较，差异均无统计学意义（

＞0.05）；肥胖（BMI＞28 kg/m

）患者的氨磺必利

值显著低于正常（BMI为18.5～23.9 kg/m

）患者；联用奥氮平、丙戊酸钠、苯二氮

http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=40144197&type=

http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=40144208&type=

http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=40144202&type=

3.17498779

3.17591858

类药物均不会影响患者的氨磺必利

值（

＞0.05）；患者的血清肌酐水平与氨磺必利给药剂量不相关（

＝0.081，

＞0.05），但与该药的

值呈正相关（

＝0.285，

＜0.05）。

结论

患者的年龄、BMI、血清肌酐水平与氨磺必利的

值密切相关。临床在应用氨磺必利治疗精神分裂症时，应充分考虑患者的年龄、体质量、血清肌酐等因素，为患者制定个体化用药方案，以保证治疗的安全、有效。

Abstract

OBJECTIVE

To analyze the influential factors for dose-corrected trough concentration （

） of amisulpride， and to provide reference for rational use of it in clinic.

METHODS

The results of the last serum concentration monitoring and relevant medical data of schizophrenic inpatients who were monitored for the treatment of amisulpride in the Mental Health Center of the First Hospital of Hebei Medical University from March to November 2021 were collected retrospectively and analyzed the effects of age， sex， body mass index （BMI）， serum creatinine level， and combined medication on the

value of amisulpride.

RESULTS

A total of 133 schizophrenic inpatients were included， and median dose of amisulpride was 600.00 mg/d， median serum concentration was 332.57 ng/mL， and median value of

was 0.61 ng·d/（mL·mg）. The serum concentration of 49 patients was within the recommended range of relevant guideline （100-320 ng/mL）， and 27 patients exceeded the laboratory warning concentration （640 ng/mL）. There was no statistical significance in drug dose， serum concentration or

value among the patients of different genders （

＞0.05）. The serum concentration of minor patients was significantly lower than that of adult patients （

＜0.05）， but there was no statistical significance in drug dose or

value between minor patients and adult patients （

＞0.05）. The

value of amisulpride in obese patients （BMI＞28 kg/m

） was significantly lower than that in normal patients （BMI 18.5-23.9 kg/m

）； the combination of olanzapine， sodium valproate and benzodiazepines did not affect the

value of amisulpride （

＞0.05）； the level of serum creatinine in patients was not related to the dose of amisulpride （

＝0.081，

＞0.05）， but was positively related to the

value of the drug （

＝0.285，

＜0.05）.

CONCLUSIONS

The age， BMI and serum creatinine level of patients are closely related to the

value of amisulpride. In the clinical treatment of schizophrenia with amisulpride， we should fully consider the patient’s age， body mass， serum creatinine and other factors， and develop a personalized drug regimen for patients to ensure the safety and effectiveness of treatment.

关键词

氨磺必利治疗药物监测剂量校正浓度影响因素联合用药

Keywords

therapeutic drug monitoringdose-corrected trough concentrationinfluential factordrug combination

references

黄善情，卢浩扬，肖桃，等. 氨磺必利药物不良反应个案报道的临床分析[J]. 中国临床药理学杂志， 2021， 37（22）： 3169-3172.

王占璋，倪晓佳，卢浩扬，等. 氨磺必利片治疗药物监测及临床应用研究[J]. 中国临床药理学杂志， 2018， 34（23）： 2704-2706， 2710.

HADRYŚ T， RYMASZEWSKA J. Amisulpride： is it as all other medicines or is it different? An update[J]. Psychiatr Pol， 2020， 54（5）： 977-989.

JOHNSEN E， KROKEN R A， LØBERG E M， et al. Amisulpride， aripiprazole， and olanzapine in patients with schizophrenia-spectrum disorders （BeSt InTro）： a pragmatic， rater-blind， semi-randomised trial[J]. Lancet Psychiatry， 2020， 7（11）： 945-954.

HIEMKE C， BERGEMANN N， CLEMENT H W， et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology： update 2017[J]. Pharmacopsychiatry， 2018， 51（1/2）： e1.

TAURINES R， FEKETE S， PREUSS-WIEDENHOFF A， et al. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone[J]. J Neural Transm （Vienna）， 2022， 129（5/6）： 689-701.

GLATARD A， GUIDI M， DELACRÉTAZ A， et al. Amisulpride： real-world evidence of dose adaptation and effect on prolactin concentrations and body weight gain by pharmacokinetic/pharmacodynamic analyses[J]. Clin Pharmacokinet， 2020， 59（3）： 371-382.

DE LEON J. Personalizing dosing of risperidone， paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics[J]. Neuropharmacology，2020，168：107656.

XU Z Y， GUO H L， LI L， et al. Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy[J]. Front Pediatr， 2020， 8： 599044.

WANG Z Z， DENG S H， LU H Y， et al. Effect of venlafaxine dosage， valproic acid concentration， sex， and age on steady state dose-corrected concentrations of venlafa- xine and O-desmethylvenlafaxine： a retrospective analysis of therapeutic drug monitoring data in a Chinese population[J]. Hum Psychopharmacol， 2020， 35（3）： e2733.

国家药典委员会. 中华人民共和国药典：四部[S].2020年版.北京：中国医药科技出版社， 2020：466-472.

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet， 2004， 363（9403）： 157-163.

HUANG S Q， LI L， WANG Z Z， et al. Modeling and simulation for individualized therapy of amisulpride in Chinese patients with schizophrenia： focus on interindividual variability， therapeutic reference range and the laboratory alert level[J]. Drug Des Devel Ther， 2021， 15： 3903-3913.

WANG S T， LI Y. Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole， amisulpride， olanzapine， paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients[J]. Biomed Chromatogr， 2017， 31（8）： e3928.

MÜLLER M J， EICH F X， REGENBOGEN B， et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder[J]. J Psychopharmacol， 2009， 23（3）： 278-286.

HOEKSTRA S， BARTZ-JOHANNESSEN C， SINKEVICIUTE I， et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder： results from the BeSt InTro study[J]. NPJ Schizophr， 2021， 7（1）： 39.

LIM S Y， PETTIT R S. Pharmacokinetic considerations in pediatric pharmacotherapy[J]. Am J Health Syst Pharm， 2019， 76（19）： 1472-1480.

WARRINGS B， SAMANSKI L， DECKERT J， et al. Impact of body mass index on serum concentrations of antidepressants and antipsychotics[J]. Ther Drug Monit， 2021， 43（2）： 286-291.

PILLINGER T， MCCUTCHEON R A， VANO L， et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia， predictors of metabolic dysregulation， and association with psychopathology： a systematic review and network meta-analysis[J]. Lancet Psychiatry， 2020， 7（1）： 64-77.

BRILL M J， DIEPSTRATEN J， VAN RONGEN A， et al. Impact of obesity on drug metabolism and elimination in adults and children[J]. Clin Pharmacokinet， 2012， 51（5）： 277-304.

HANLEY M J， ABERNETHY D R， GREENBLATT D J. Effect of obesity on the pharmacokinetics of drugs in humans[J]. Clin Pharmacokinet， 2010， 49（2）： 71-87.

VERHAEGEN A A， VAN GAAL L F. Drug-induced obesity and its metabolic consequences： a review with a focus on mechanisms and possible therapeutic options[J]. J Endocrinol Invest， 2017， 40（11）： 1165-1174.

LIANG J Q， CAI Y S， XUE X Y， et al. Does schizophrenia itself cause obesity? [J]. Front Psychiatry， 2022， 13： 934384.

SCHMIDT-KRAEPELIN C， FEYERABEND S， ENGELKE C， et al. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany （COMBINE）： a double-blind randomised controlled trial[J]. Lancet Psychiatry， 2022， 9（4）： 291-306.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors

抗高血压药物靶标及剂型的研发进展

我院2012年抗高血压药物门诊处方分析Δ

丹参素与川芎嗪复方制剂治疗心脑血管疾病的进展

某院住院患者甲硝唑联用情况分析

Related Author

WANG Hongmei

DONG Lin

SHU Yishuo

DONG Zhonghua

YI Qiaoyan

LI Hongjuan

GU Yan

HAN Yan

Related Institution

Dept. of Hematology， the First Affiliated Hospital of Shandong First Medical University（Shandong Provincial Qianfoshan Hospital）

Dept. of Clinical Pharmacy， the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy

Dept. of Pediatrics， the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰